PHK
ANAB icon

Point72 Hong Kong’s AnaptysBio ANAB Stock Holding History

Point72 Hong Kong’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-366
Closed -$13K – 1810
2021
Q4 		$13K Buy
+366
New +$11.6K ﹤0.01% 1606
2019
Q4 		– Sell
-320
Closed -$11K – 1135
2019
Q3 		$11K Buy
+320
New +$15.2K ﹤0.01% 749

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Hong Kong's ANAB Position: Q1 2022 in Review

Point72 Hong Kong sold out of AnaptysBio (ANAB) in Q1 2022, closing a stake of 366 shares — an estimated $13K sold.

Point72 Hong Kong first reported a position in ANAB in Q3 2019 and held it in 2 quarters. The position peaked at $13K in Q4 2021. 131 funds tracked by Wall St. Rank hold ANAB as of Q1 2022.

  • Point72 Hong Kong reported no remaining AnaptysBio position as of Q1 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 366 AnaptysBio shares in Q1 2022, an estimated $13K.
  • Point72 Hong Kong first reported a position in AnaptysBio in Q3 2019 and held it in 2 quarters.
  • Point72 Hong Kong's AnaptysBio position peaked at $13K in Q4 2021.
  • 131 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2022.

Based on Point72 Hong Kong's 13F filing for Q1 2022, filed 16 May 2022.